Medical - Devices
Compare Stocks
5 / 10Stock Comparison
CATX vs LNTH vs AGEN vs RNW vs EXAS
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Biotechnology
Renewable Utilities
Medical - Diagnostics & Research
CATX vs LNTH vs AGEN vs RNW vs EXAS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic | Biotechnology | Renewable Utilities | Medical - Diagnostics & Research |
| Market Cap | $267M | $5.92B | $132M | $1.33B | $20.02B |
| Revenue (TTM) | $576K | $1.55B | $114M | $129.66B | $3.25B |
| Net Income (TTM) | $-114M | $279M | $115K | $11.97B | $-208M |
| Gross Margin | -150.2% | 60.5% | 35.7% | 77.9% | 69.7% |
| Operating Margin | -184.6% | 18.8% | -17.7% | 48.4% | -6.4% |
| Forward P/E | — | 17.5x | 1.8x | 0.4x | 582.8x |
| Total Debt | $4M | $738K | $10M | $732.28B | $2.52B |
| Cash & Equiv. | $62M | $359M | $3M | $40.42B | $956M |
CATX vs LNTH vs AGEN vs RNW vs EXAS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| Perspective Therape… (CATX) | 100 | 25.7 | -74.3% |
| Lantheus Holdings, … (LNTH) | 100 | 487.2 | +387.2% |
| Agenus Inc. (AGEN) | 100 | 4.7 | -95.3% |
| ReNew Energy Global… (RNW) | 100 | 49.1 | -50.9% |
| Exact Sciences Corp… (EXAS) | 100 | 75.9 | -24.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CATX vs LNTH vs AGEN vs RNW vs EXAS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CATX is the clearest fit if your priority is income & stability.
- Dividend streak 1 yrs, beta 1.58
LNTH has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs EXAS's 16.7%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
- 18.0% margin vs CATX's -197.3%
- 12.4% ROA vs CATX's -36.6%, ROIC 30.6% vs 5.2%
Among these 5 stocks, AGEN doesn't own a clear edge in any measured category.
RNW is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 19.4%, EPS growth 10.1%, 3Y rev CAGR 17.8%
- 19.4% revenue growth vs CATX's -100.0%
- Lower P/E (0.4x vs 582.8x)
EXAS ranks third and is worth considering specifically for defensive.
- Beta 0.12, current ratio 2.43x
- Beta 0.12 vs AGEN's 2.72
- +96.9% vs RNW's -17.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.4% revenue growth vs CATX's -100.0% | |
| Value | Lower P/E (0.4x vs 582.8x) | |
| Quality / Margins | 18.0% margin vs CATX's -197.3% | |
| Stability / Safety | Beta 0.12 vs AGEN's 2.72 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +96.9% vs RNW's -17.7% | |
| Efficiency (ROA) | 12.4% ROA vs CATX's -36.6%, ROIC 30.6% vs 5.2% |
CATX vs LNTH vs AGEN vs RNW vs EXAS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CATX vs LNTH vs AGEN vs RNW vs EXAS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RNW leads in 1 of 6 categories
LNTH leads 1 • EXAS leads 1 • CATX leads 0 • AGEN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RNW leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RNW is the larger business by revenue, generating $129.7B annually — 225100.5x CATX's $576,000. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to CATX's -197.3%. On growth, RNW holds the edge at +37.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $576,000 | $1.5B | $114M | $129.7B | $3.2B |
| EBITDAEarnings before interest/tax | -$104M | $347M | -$10M | $86.9B | -$41M |
| Net IncomeAfter-tax profit | -$114M | $279M | $115,000 | $12.0B | -$208M |
| Free Cash FlowCash after capex | -$112M | $372M | -$159M | -$23.8B | $357M |
| Gross MarginGross profit ÷ Revenue | -150.2% | +60.5% | +35.7% | +77.9% | +69.7% |
| Operating MarginEBIT ÷ Revenue | -184.6% | +18.8% | -17.7% | +48.4% | -6.4% |
| Net MarginNet income ÷ Revenue | -197.3% | +18.0% | +0.1% | +9.2% | -6.4% |
| FCF MarginFCF ÷ Revenue | -195.2% | +24.0% | -139.1% | -18.4% | +11.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +1.2% | +27.5% | +37.2% | +23.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +76.5% | +85.3% | +94.8% | +90.4% |
Valuation Metrics
Evenly matched — AGEN and RNW each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 26.7x trailing earnings, LNTH trades at a 43% valuation discount to RNW's 46.9x P/E. On an enterprise value basis, RNW's 11.3x EV/EBITDA is more attractive than CATX's 20.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $267M | $5.9B | $132M | $1.3B | $20.0B |
| Enterprise ValueMkt cap + debt − cash | $210M | $5.6B | $140M | $8.6B | $21.6B |
| Trailing P/EPrice ÷ TTM EPS | -2.93x | 26.69x | -1102.94x | 46.91x | -95.37x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.52x | 1.79x | 0.40x | 582.83x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 20.06x | 14.61x | — | 11.27x | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.84x | 1.16x | 1.30x | 6.16x |
| Price / BookPrice ÷ Book value/share | 0.80x | 5.72x | — | 1.43x | 8.24x |
| Price / FCFMarket cap ÷ FCF | — | 16.73x | — | — | 56.10x |
Profitability & Efficiency
LNTH leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-43 for CATX. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RNW's 5.59x. On the Piotroski fundamental quality scale (0–9), EXAS scores 7/9 vs RNW's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -42.8% | +24.3% | — | +8.4% | -8.7% |
| ROA (TTM)Return on assets | -36.6% | +12.4% | +0.1% | +1.2% | -3.5% |
| ROICReturn on invested capital | +5.2% | +30.6% | — | +4.9% | -3.6% |
| ROCEReturn on capital employed | +5.2% | +17.1% | — | +6.9% | -4.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 6 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x | — | 5.59x | 1.05x |
| Net DebtTotal debt minus cash | -$58M | -$358M | $7M | $691.9B | $1.6B |
| Cash & Equiv.Liquid assets | $62M | $359M | $3M | $40.4B | $956M |
| Total DebtShort + long-term debt | $4M | $738,000 | $10M | $732.3B | $2.5B |
| Interest CoverageEBIT ÷ Interest expense | -948.77x | 11.72x | 1.11x | 86.76x | -5.47x |
Total Returns (Dividends Reinvested)
Evenly matched — LNTH and EXAS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $611 for AGEN. Over the past 12 months, EXAS leads with a +96.9% total return vs RNW's -17.7%. The 3-year compound annual growth rate (CAGR) favors EXAS at 15.2% vs AGEN's -51.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +29.0% | +35.3% | +16.1% | -7.8% | +3.1% |
| 1-Year ReturnPast 12 months | +53.2% | +13.1% | +27.1% | -17.7% | +96.9% |
| 3-Year ReturnCumulative with dividends | -46.2% | -4.0% | -88.2% | +4.4% | +53.0% |
| 5-Year ReturnCumulative with dividends | -59.0% | +314.2% | -93.9% | -45.7% | +0.4% |
| 10-Year ReturnCumulative with dividends | -66.4% | +4192.5% | -94.3% | -50.5% | +1669.1% |
| CAGR (3Y)Annualised 3-year return | -18.7% | -1.4% | -51.0% | +1.5% | +15.2% |
Risk & Volatility
EXAS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EXAS is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs AGEN's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.58x | 0.47x | 2.72x | 0.62x | 0.12x |
| 52-Week HighHighest price in past year | $6.16 | $93.00 | $7.34 | $8.24 | $104.98 |
| 52-Week LowLowest price in past year | $1.96 | $47.25 | $2.71 | $4.38 | $38.81 |
| % of 52W HighCurrent price vs 52-week peak | +58.4% | +97.8% | +51.1% | +65.5% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 39.3 | 61.2 | 48.8 | 64.1 | 76.4 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 886K | 814K | 734K | 4.2M |
Analyst Outlook
Evenly matched — CATX and AGEN and RNW each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CATX as "Buy", LNTH as "Buy", AGEN as "Buy", RNW as "Buy", EXAS as "Buy". Consensus price targets imply 226.4% upside for CATX (target: $12) vs -1.6% for EXAS (target: $103).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $11.75 | $101.00 | $7.33 | $6.52 | $103.18 |
| # AnalystsCovering analysts | 11 | 17 | 11 | 6 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 1 | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.1% | +0.1% | 0.0% | +0.1% |
RNW leads in 1 of 6 categories (Income & Cash Flow). LNTH leads in 1 (Profitability & Efficiency). 3 tied.
CATX vs LNTH vs AGEN vs RNW vs EXAS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CATX or LNTH or AGEN or RNW or EXAS a better buy right now?
For growth investors, ReNew Energy Global Plc (RNW) is the stronger pick with 19.
4% revenue growth year-over-year, versus -100. 0% for Perspective Therapeutics, Inc. (CATX). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Perspective Therapeutics, Inc. (CATX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CATX or LNTH or AGEN or RNW or EXAS?
On trailing P/E, Lantheus Holdings, Inc.
(LNTH) is the cheapest at 26. 7x versus ReNew Energy Global Plc at 46. 9x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CATX or LNTH or AGEN or RNW or EXAS?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CATX or LNTH or AGEN or RNW or EXAS?
By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.
12β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 2159% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.
05Which is growing faster — CATX or LNTH or AGEN or RNW or EXAS?
By revenue growth (latest reported year), ReNew Energy Global Plc (RNW) is pulling ahead at 19.
4% versus -100. 0% for Perspective Therapeutics, Inc. (CATX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -44. 7% for Perspective Therapeutics, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CATX or LNTH or AGEN or RNW or EXAS?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus -197. 3% for Perspective Therapeutics, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -184. 6% for CATX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CATX or LNTH or AGEN or RNW or EXAS more undervalued right now?
On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.
4x forward P/E versus 582. 8x for Exact Sciences Corporation — 582. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CATX: 226. 4% to $11. 75.
08Which pays a better dividend — CATX or LNTH or AGEN or RNW or EXAS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CATX or LNTH or AGEN or RNW or EXAS better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1669% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CATX and LNTH and AGEN and RNW and EXAS?
These companies operate in different sectors (CATX (Healthcare) and LNTH (Healthcare) and AGEN (Healthcare) and RNW (Utilities) and EXAS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CATX is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; RNW is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.